Administracion

Curr Opin HIV AIDS. 2009 Sep;4(5):358-63.

Specificity of the autologous neutralizing antibody response.

Moore PL, Gray ES, Morris L.
AIDS Virus Research Unit, National Institute forCommunicable Diseases, Johannesburg, South Africa. pennym@nicd.ac.za
PURPOSE OF REVIEW: It has long been known that autologous neutralizing antibodies (AnAbs) exert pressure on the envelope of HIV, resultingin neutralization escape. However, recently, progress has been made in uncovering the precise targets of these potent early antibodies. RECENT FINDINGS: AnAbs primarily target variable regions of theHIV-1 envelope, explaining the strain-specificity of these antibodies. Despite high neutralizing potential and cross-reactivity, anti-V3 antibodies do not contribute to autologous neutralization. TheV1V2 is commonly immunogenic in early HIV-1 and simian human immunodeficiency virus infections, though the nature of these epitopes remains to be determined. In subtype C viruses, the C3 region is aneutralization target, possibly as a result of its more exposed and amphipathic structure. Autologous neutralization appears to be mediated by very few AnAb specificities that develop sequentiallysuggesting the possibility of immunological hierarchies for both binding and neutralizing antibodies. The role of AnAbs in preventing superinfection and in restricting virus replication is reexamined inthe context of recent data. SUMMARY: New studies have greatly contributed toward our understanding of the specificities mediating autologous neutralization and highlighted potential vulnerabilities ontransmitted viruses. However, the contribution of AnAbs to the development of neutralization breadth remains to be characterized.
PMID: 20048698 [PubMed - indexed for MEDLINE]
urr Opin Drug DiscovDevel. 2008 Sep;11(5):675-87.

Antibody therapeutics, antibody engineering, and the merits of protein stability.

Demarest SJ, Glaser SM.
Biogen Idec, 5200 Research Place, San Diego, CA 92122,...